Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations

[Image: see text] Nearly a century after its first description, configurationally stable axial chirality remains a rare feature in marketed drugs. In the development of the KRAS(G12C) inhibitor sotorasib (LUMAKRAS/LUMYKRAS), an axially chiral biaryl moiety proved a critical structural element in eng...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanman, Brian A., Parsons, Andrew T., Zech, Stephan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583618/
https://www.ncbi.nlm.nih.gov/pubmed/36178208
http://dx.doi.org/10.1021/acs.accounts.2c00479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583618/
https://www.ncbi.nlm.nih.gov/pubmed/36178208
http://dx.doi.org/10.1021/acs.accounts.2c00479

Ejemplares similares